[Inhaled corticosteroid therapy and bone metabolism in @entity748 XXXX ].

@entity1 @entity748 @entity79 @entity4185 @entity2331
OBJECTIVE: To explore the association between @entity4185 ( @entity4185 ) therapy and bone metabolism. @entity1 AND METHODS: The sample was composed of 151 @entity1 , aged between 1 and 17 years. There were 71 @entity748 treated with @entity4185 for at least 6 months (group 1), 44 @entity748 treated occasionally with @entity4185 during exacerbations (group 2), and 36 healthy @entity1 (group 3). @entity79 ( @entity79 ) and markers of bone formation and resorption were measured. These measures, as well as other related factors, were compared among groups. Regression models for @entity2331 and @entity79 were used with the group as the independent variable adjusted by factors with differences between groups. A two-tailed level of p < 0.05 was used in all tests. RESULTS: No differences in @entity79 were found between groups 1 and 2 but significant differences were found between groups 1 and 3 (p = 0.003). No differences were found in markers of bone formation and resorption among the groups. No association was found between @entity79 and the type, daily dose or accumulated dose of @entity4185 . Group 1 showed an @entity2331 odds ratio relative to group 3 of 2.94 (95 % CI: 1.49-5.78) and an average reduction of @entity79 of 0.50 (95 % CI: 0.32-0.68) was found from group 3 to 2 and from group 2 to 1. In group 1, markers of bone resorption significantly increased in @entity748 with @entity2331 compared with those without @entity2331 . CONCLUSIONS: @entity4185 treatment in @entity748 @entity1 seems to affect @entity79 . Markers of bone formation and resorption are unaffected. @entity2331 in these @entity1 could also be related to other factors that increase bone resorption.
